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PCARDIOVASCULAR GENOMIC MEDICINE
Genomics
The Next Step to Elucidate the
Etiology of Calcific Aortic Valve Stenosis
Yohan Bossé, PHD,*† Patrick Mathieu, MD,‡ Philippe Pibarot, DVM, PHD, FACC, FAHA§
Quebec City, Quebec, Canada
With the current shift toward an older population, calcific aortic valve stenosis (AVS) is likely to become a major
societal and economic burden. For many years, AVS was regarded as a degenerative and nonmodifiable process.
However, molecular studies unanimously demonstrated that AVS is an actively regulated disorder with several
potential therapeutic targets. Many factors are predicted to cause AVS, and an important genetic predisposition
is anticipated. In this review, we describe candidate genes and signaling pathways identified by genetic research
and incorporate this new knowledge into a more comprehensive picture of factors involved in the pathogenesis
of AVS. We also emphasize the need for additional studies to elucidate its complete genetic architecture. Recent
advances in genomic research offer a remarkable opportunity to investigate AVS at the most fundamental level.
The benefits of these new approaches can be observed in many complex diseases, but the field of AVS is trailing
behind. We discuss the future utility of these new genomic approaches to improve our understanding of AVS and
to refine the management of patients in terms of diagnosis, prevention, and treatment. (J Am Coll Cardiol
2008;51:1327–36) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.12.031c
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calvular heart diseases are an important and growing public-
ealth problem (1–4). Aortic valve diseases are frequently the
onsequence of congenital malformations or rheumatic fever
5). However, degenerative (senile) calcification of aortic
alves, or calcific aortic valve disease, is increasing in prevalence
nd has become the most common indication for surgical valve
eplacement (6). Calcific aortic valve disease is characterized by
athological remodeling and calcification processes leading to
arying degrees of morphologic changes of the aortic valve
usps, including irregular areas of increased thickening, distor-
ion, rigidity, fibrosis, and the presence of cartilaginous or bone
odules. The disease has been divided into two functional
ategories, aortic valve sclerosis and aortic valve stenosis (AVS).
his distinction is based on the obstruction of the left ventric-
lar outflow track, which is absent in aortic valve sclerosis
morphologic changes of the valve without functional abnor-
ality) and present in AVS (morphologic and functional valve
bnormalities). Although this classification is useful in the
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007, accepted December 10, 2007.linical setting, it simply categorizes an early and more ad-
anced stage of the same disease. Indeed, calcific aortic valve
isease is recognized to be a slowly progressive disorder, with a
isease continuum beginning with aortic valve sclerosis lesions
haring many similarities with early atherosclerotic plaques but
hich may subsequently progress toward severe calcification
nd valvular stenosis (7).
The prevalence of calcific aortic valve disease, with or
ithout congenitally malformed valves, increases exponen-
ially with age. In industrialized societies, aortic valve
clerosis is present in more than 25% of patients older than
ge 65 years (8), and is associated with a 50% increased risk
f cardiovascular events (9). It is suspected that aortic valve
clerosis is a marker for a systemic atherosclerotic process.
oreover, it is generally assumed that aortic valve sclerosis
epresents an early stage of the disease process that may
ubsequently lead to the development of AVS. In fact, it is
ocumented that over a short period of time (5 years)
pproximately 9% of individuals with an aortic valve scle-
osis will progress to AVS (10). On the other hand, severe
VS is found in 2% to 5% of elderly subjects (8,11) and
s associated with a poor prognosis, with a 80% 5-year
isk of death, valve replacement, or progression to heart
ailure (12). Current management of these patients fo-
uses on the development of symptoms to determine the
iming of surgical valve replacement. Aortic valve stenosis
as become the second most common indication for
ardiac surgery (13). The American Heart Association
tatistics Committee estimated that 99,000 valve proce-
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Genomics of AVS April 8, 2008:1327–36dures were performed in the
U.S. in 2004. The mean esti-
mated cost for each surgery is
nearly $120,000 (1). Accord-
ingly, AVS is now considered
to be a major societal and eco-
nomic burden. With recent
medical advances resulting in
increased longevity, the preva-
lence of AVS is expected to rise
significantly in the near future
14). Therefore, the health and socioeconomic burden
ssociated with AVS is likely to increase substantially.
Abbreviations
and Acronyms
AVS  aortic valve
stenosis
IL  interleukin
SNP  single nucleotide
polymorphism
TGF  transforming growth
factor
Figure 1 Pathogenesis of Calcific AVS
(A) Current understanding of factors leading to aortic valve stenosis (AVS). All of t
at the base of the triangle. The next layers show: 1) environmental and clinical fac
AVS. Each layer affects subsequent layers and leads to the final manifestation of
genetic and nongenetic, exist in a dynamic network that operates throughout the l
ual 1) carries a high genetic predisposition and develops AVS by the age of 65 ye
makeup and develops AVS 2 decades later. (C) Drawing of an aortic valve illustrat
interplay between cells, molecular mediators, and pathways is depicted in the bloo
genic lipoproteins infiltrate the endothelial layer. The extracellular lipids are subse
the subendothelial region release cytokines, such as tumor necrosis factor- (TNF-),
local production of matrix metalloproteins (MMPs), which contribute to extracellula
protein. The angiotensin-converting enzyme (ACE) that is colocalized with apolipopr
lates fibroblast expression of lipoprotein-retaining proteoglycan that trap lipids with
sion of bone morphogenic protein 2 (BMP2) and promotes osteogenic signaling pa
the differentiation of fibroblast/myofibroblast to an osteoblast phenotype. These m
Recently, it was shown that NOTCH1 inhibits osteoblast differentiation by repressiMany factors have been proposed to explain the cause of
alcific aortic valve disease (Fig. 1). First, congenitally
icuspid aortic valve, present in 1% to 2% of the population,
s a major factor contributing to AVS. During their lifetime,
ost individuals with congenital bicuspid valves develop
ortic valve pathology, mostly AVS, whereas only 1%
emain with a normal valve function (15). Subjects with a
icuspid valve develop AVS 1 or 2 decades earlier than those
ith a tricuspid valve. It is suspected that hemodynamic
lterations induced by bicuspid aortic valves may accelerate
he calcifying process. However, intrinsic biological abnor-
alities may coexist and contribute to early remodeling of
alvuloarterial components in these patients. Whereas con-
es reported to be associated with AVS in at least 1 published study are shown
) metabolic and signaling pathways; and 3) cellular processes associated with
ease. An extra level of complexity arises from the fact that all factors, both
of an individual. (B) Two possible disease histories. The first individual (individ-
contrast, the second individual (individual 2) has a more favorable genetic
metabolic, signaling, and cellular processes involved in AVS. The potential
partment and in the subendothelial region. First, inflammatory cells and athero-
y taken up by macrophages to become foam cells. Activated T lymphocytes within
rming growth factor-1 (TGF-1), and interleukin-1 (IL-1). Interleukin-1 increases
ix remodeling. Macrophages also express osteopontin (OPN), a bone-associated
B generates angiotensin II (AngII) from angiotensin I (AngI). Angiotensin II stimu-
subendothelial compartment. The atherogenic milieu up-regulates the expres-
s such as Runx2/Cbfa1 and Wnt/Lrp5/-catenin pathways, which are involved in
d cells then favor the development of calcium nodules and bone formation.
Runx2/Cbfa1 pathway (67). BMI  body mass index.he gen
tors; 2
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April 8, 2008:1327–36 Genomics of AVSenital abnormality and age are both irrefutable risk factors
or AVS, other risk factors have been documented. In fact,
pidemiologic studies have identified many clinical risk
actors for AVS, including smoking, male gender, hyper-
ension, hypercholesterolemia, elevated body mass index,
nd diabetes (8,16). In one study, serum creatinine and
alcium concentrations were also correlated with the pro-
ression of AVS (17). More recently, the metabolic syn-
rome also has been associated with a higher prevalence of
ortic valve sclerosis (18) and with faster disease progression
nd poorer clinical outcomes in patients with AVS (19).
inally, a genetic predisposition to AVS also was demon-
trated (see subsequent text).
In this state-of-the-art review, we present a comprehen-
ive overview of genetic studies conducted to elucidate the
enetic architecture of AVS. Epidemiologic studies quanti-
ying the genetic component of the disease are summarized.
compilation of candidate gene association studies is then
rovided. The findings derived from these studies are then
ncorporated into the current context of knowledge vis-à-vis
he cellular processes and signaling pathways involved in
VS. Finally, recent developments in genomic research and
echnologies, which promise to accelerate the pace of
iscoveries in complex diseases such as AVS, are discussed.
olecular Understanding of AVS
or many years, AVS has been regarded as a degenerative
isease deriving from a “wear and tear” process (20).
owever, for the past decade molecular studies have laid
ome groundwork in defining the genes and molecular
athways involved in the pathological process. In this
ection, we describe how a disease previously known as a
assive degenerative process is now convincingly demon-
trated as a complex pathobiological disorder.
All molecular studies so far support the hypothesis that
ortic valve calcification is an active cellular process involv-
ng multiple cell signaling pathways. In vitro experiments
ave clearly demonstrated that valve interstitial cells have
he ability to form calcified nodules and to change their
henotype toward osteoblast-like cells when grown in ap-
ropriate conditions (21). Furthermore, histopathological
eatures of human aortic valves removed at surgery or
ecropsy were the first to support the hypothesis that aortic
alve stenosis is the result of an active inflammatory cellular
rocess characterized by lipoprotein deposition and molec-
lar mediators of calcification (22–27). Infiltration by in-
ammatory cells was observed in early degenerative valve
esions, including macrophages, T lymphocytes, and mast
ells (28,29). In addition, these valves accumulate oxidized
ipid and apolipoproteins (28,30). Aortic valve lesions also
ontain a number of proinflammatory cytokines, such as
nterleukin (IL)-1 (31) and tumor necrosis factor- (32),
s well as a number of matrix metalloproteinases (31–33) and
eovascularization-promoting factors (34) believed to enhance
issue remodeling. Thus, an intricate process involving molec- Rlar and cellular responses that regulate extracellular matrix
rganization is involved in the pathogenesis of AVS (35).
aken together, these studies suggest a common cellular basis
or the genesis of valvular and vascular diseases (36).
A number of studies have also suggested that the renin-
ngiotensin system is involved in aortic valve lesion patho-
enesis (26,29). All major components of the renin-
ngiotensin system are found in valve lesions, including
ngiotensin-converting enzyme, angiotensin II, and angio-
ensin II type 1 receptor. This system is believed to promote
esion progression by stimulating cellular proliferation and
roteoglycan synthesis by fibroblasts, which in turn stimu-
ates the production of reactive oxygen species, including
eroxynitrite, through the inducible nitric oxide synthase
athway (37). Recently, in a rodent model of AVS, Weiss
t al. (38) reported that aging was associated with increased
roduction of superoxide within calcified aortic valves. On
he other hand, in hypercholesterolemic rabbits, expression
f endothelial nitric oxide synthase is decreased (39), and
he absence of this enzyme in mice causes abnormal con-
enital aortic valve development (40). Therefore, complex
nteractions regulating nitric oxide production are likely to
lay an active role in the pathogenesis of calcific aortic valve
iseases.
Calcification and matrix remodeling is a defining feature
f AVS (41). Moreover, bone and cartilage formation occur
n 10% to 15% of explanted AVS valves. A growing body of
vidence is now supporting that ectopic calcification is a
ell-regulated process involving the transformation of valve
broblast into osteoblast-like cells (21,22,27). Earlier mo-
ecular studies performed in human aortic valves demon-
trated the up-regulation of molecular calcification markers,
ncluding osteocalcin, osteopontin, and Runx2 (27,42,43).
unx2, also known as Cbfa1, is a central transcriptional
egulator of osteoblasts. Runx2/Cbfa1 is also up-regulated
n mouse and rabbit models of valvular calcification (44,45).
he importance of Runx2/Cbfa1 in calcification was dem-
nstrated in knockout mice characterized by bones that do
ot calcify and remain cartilaginous (46). Runx2/Cbfa1 can
e activated by the bone morphogenic protein 2, which is
resent in human aortic valve lesions (47). The protein is
ctivated by atherogenic factors, such as oxidized lipids,
hich are found in valvular lesions (30). Accordingly,
ipid-derived products from oxidation present in valve le-
ions can promote calcification by activating the osteogenic
unx2/Cbfa1 pathway via BMP2 (23). Interestingly,
MP2 is also known to up-regulate the transcription factor
sx2, which is an activator of the Wnt signaling pathway.
ecently, Rajamannan et al. (48) suggested that the Wnt/
ow-density lipoprotein receptor-related protein 5 (Lrp5)/
-catenin pathway may be involved in valvular calcification.
aken together, these results suggested that the activation
f BMP2 by atherogenic factors found in valve lesions
timulate 2 osteogenic signaling pathways, namely the
unx2/Cbfa1 and the Wnt/Lrp5/-catenin pathways.
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Genomics of AVS April 8, 2008:1327–36hese activated pathways subsequently promote osteoblas-
ogenesis and the formation of extraosseous calcification.
Molecular studies conducted over the past decade pro-
ided evidence that supports the implication of active
olecular and cellular processes in the pathogenesis of
VS. This includes specific cell signaling pathways regulat-
ng vascular calcification, inflammation, and remodeling as
ell as other biological processes such as subendothelial
eposition and retention of atherogenic lipoproteins, acti-
ation of the renin-angiotensin system, and neovasculariza-
ion. The implication of all these cellular, metabolic, and
ignaling pathways provides a strong impetus for the real-
zation of future research to quantify the genetic contribu-
ion in the development and progression of AVS and to
dentify the causal or susceptibility variants.
enetics of AVS
enetic epidemiology. Most of the genetic epidemiologic
tudies performed on valvular diseases have focused on
ongenital valve defects. Bicuspid aortic valve, the most
ommon congenital cardiovascular abnormality, was long
onsidered to be a sporadic and isolated event. However,
arlier studies described familial patterns compatible with
enetic inheritance (49), along with a higher rate of occur-
ence in the first-degree relatives of affected patients (50).
ubsequently, a larger study estimated the heritability coef-
cient at 89%, suggesting that the bicuspid aortic valve is
lmost entirely genetic in nature (51). Interestingly, a recent
enome-wide linkage scan performed in 38 families identi-
ed 3 loci on chromosome 18q, 5q, and 13q which likely
arbor genes responsible for bicuspid aortic valve (52).
trong inheritance was also observed for nonsyndromic left
entricular outflow tract obstruction, which consists in an
natomically varied set of defects including bicuspid aortic
alve, coarctation of the aorta, aortic valve stenosis, and
ypoplastic left heart (53,54). Similarly, a population data-
ase from Utah, composed of large pedigrees, demonstrated
hat death resulting from aortic and mitral valve diseases
lustered among relatives, suggesting a significant genetic
ffect for death caused by valvular diseases (55). Despite this
lear genetic contribution, however, the mode of inheritance
f valvular diseases is unclear and is most likely explained by the
ction of many genes. Nevertheless, these studies demonstrated
hat valvular diseases aggregate within families and clearly
ustified echocardiography screening of first-degree relatives of
ffected individuals.
Apart from the bicuspid valve, no heritability and inher-
tance studies have been reported on calcific aortic valve
isease. The complexity lies in collecting family data for a
isease that occurs late in life. Usually, data for the parents
nd grandparents of affected patients are not available and
annot be obtained. Affected sib pair or relative pair
pproaches might be a good solution for quantifying the
enetic contribution of AVS. However, collecting samples
f sufficient size remains a challenge. One epidemiologic gtudy conducted in 283 communes located in the Finistère
egion of France supports the genetic hypothesis of AVS
56). The authors calculated the prevalence of patients who
ad undergone aortic valve replacement for AVS in each
ommune. Patients with bicuspid aortic valves were excluded.
he authors then classified each commune into 1 of 3 risk
ategories and analyzed the number of adjacent concordant
ommunes. The results indicated that communes classified
s high risk were more concordant with adjacent communes
han might have been expected by chance alone, which
uggests a geographic clustering of patients who have
ndergone aortic valve replacement for AVS. Similarly,
robst et al. (57) showed a highly heterogeneous geographic
istribution of patients operated on for AVS in the western
art of France. In addition, they identified 5 families with
any affected members, demonstrating a clear familial
ggregation of the disease. Although these studies offer
upport for the genetic hypothesis, they do not show
hether shared genes or environmental factors are respon-
ible for the geographic clustering. A conclusive proof
upporting the concept that a genetic predisposition is
nvolved in AVS development would come from the dem-
nstration of causal or susceptibility genes, which remains to
e firmly established. Currently, only a handful of studies
ave focused on gene discovery.
enetic association studies. A small number of studies
ave tried to elucidate the genetic variants and genes
ssociated with AVS (Table 1). These studies have provided
ome preliminary data suggesting the contribution of a few
enes. The first of these reports was conducted on a genetic
ariant located in the vitamin D receptor gene, called BsmI
58). This study was performed in a case-control series of
00 patients with AVS (aortic valve area 1.0 cm2 or mean
ortic valve gradient 40 mm Hg) and 100 control subjects
ree of AVS as determined by cardiac catheterization.
ontrol subjects were also matched for age, gender, and
oronary artery disease. Association analyses indicated that
he B allele frequency was significantly higher in patients
han in control subjects. A second study conducted in 802
atients undergoing transthoracic echocardiography identi-
ed 43 patients with AVS defined as an aortic valve area of
1.8 cm2 and a mean aortic valve gradient of 10 mm Hg
59). A greater prevalence of APOE 2/4 and 3/4 genotypes
as observed in patients with AVS compared with patients
ithout AVS. This association was independent of age,
ender, coronary artery disease, and low-density lipoprotein
holesterol. A third study investigated whether polymor-
hisms in the estrogen receptor (ER)  gene and in the
ransforming growth factor (TGF)-1 gene were associated
ith aortic valvular sclerosis in a small case-control series of
ost-menopausal women (60). All case subjects underwent
ortic valve replacement with an aortic valve area of 1.3
m2. Control subjects were matched for age and gender and
ere free from significant aortic sclerosis as determined by
chocardiography. The PvuII polymorphism of the ER
ene was independently associated with an increased risk of
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April 8, 2008:1327–36 Genomics of AVSortic sclerosis. The combination of the PvuII and the AocI
olymorphisms in the ER and the TGF-1 genes, respec-
ively, was also associated with aortic sclerosis. A fourth
tudy found a higher prevalence of the apo B XbaI poly-
orphism and the apo E2 allele in nondiabetic patients
ith severe isolated AVS (aortic valve gradient 60 mm
g) compared with a control group free of AVS as assessed
y echocardiography and matched for age, gender, body
ass index, hypertension, and lipid/lipoprotein levels (61).
inally, 3 promoter polymorphisms (1082, 819, and
592) in the IL-10 gene were significantly associated with
he degree of calcification measured by atomic absorption
pectroscopy in 187 surgically excised stenotic aortic valves
62). In the same study, a 32-basepair deletion in the
hemokine receptor 5 and a promoter polymorphism
447) in the connective tissue growth factor genes were
lso shown to influence the degree of calcification.
Taken together, these studies suggest that individuals
ith a certain genetic background may be at higher risk of
eveloping AVS. However, these studies suffer from major
imitations and do not meet the current criteria for high-
uality genetic association studies (63,64), although this was
ot necessarily obvious at the time of their publication.
irst, the number of patients in these studies is relatively
mall. The small sample sizes may reflect the complexity of
ollecting and phenotyping patients with AVS. Neverthe-
ess, small sample sizes are more likely to give false-positive
esults (65). Accordingly, the role of the polymorphisms
ust be confirmed in larger studies before firm conclusions
an be drawn. Another major limitation is the use of only 1
r a few polymorphisms in each gene. Lessons from the
nternational HapMap Project (66) indicate the proper
enetic Association Studies on AVS
Table 1 Genetic Association Studies on AVS
Author
(Ref. #)
Study
Population Phenotype
Ortlepp et al. (58) German AVS 100 ca
mat
CAD
Avakian et al. (61) Brazilian Isolated AVS* 62 cas
(age
hype
cont
Nordström et al. (60) Caucasian post-menopausal
women (Sweden)
AVS 41 cas
(age
cont
Novaro et al. (59) Patients from the
Preventive Cardiology
database (U.S.)
AVS 43 pat
with
Ortlepp et al. (62) Patients with AS (German) Calcification 187 pa
Normal left ventricular function and no evidence of coronary artery disease.
APO  apolipoprotein; AVS  aortic valve stenosis; BAV  bicuspid aortic valve; BMI  body
ransforming growth factor; VDR  vitamin D receptor.umber of genetic variants that need to be genotyped to Hapture most of the genetic information within a gene. In
ost cases, many variants need to be genotyped to test a
ene comprehensively. So far, all the gene association
tudies with AVS have been performed incompletely. It is
lso unclear whether genes associated with AVS act directly
n the disease process or mediate their effect via other
raditional risk factors. For instance, polymorphisms in the
polipoprotein genes may alter blood lipids that are known
isk factors for AVS. To rectify this problem, large sample
izes of patients who are very well characterized at the
linical and environmental levels will be essential. Standards
o determine the disease status are also urgently needed.
one of the genetic studies described above used the same
riteria to establish the disease status. Replication of positive
enetic findings in different populations may be very difficult
f patients are defined using different criteria.
iscovering NOTCH1 as a causal gene for AVS. Re-
ently, a major breakthrough in the genetics of aortic valve
isease was made when the Notch1 signaling pathway was
dentified (67). From a genome-wide scan of a 5-generation
amily suffering from aortic valve diseases (Figs. 2A and
B), the authors identified linkage on chromosome 9q34–
5. After reviewing genes in the region, they focused on the
OTCH1 gene. They then identified a specific mutation
abelled R1108X, which causes a premature stop codon
Fig. 2C). All affected subjects had the mutant allele, which
as not detected in unaffected family members or in 1,136
nrelated subjects of diverse ethnicity. The same authors
lso found a second mutation in the NOTCH1 gene
egregating with aortic valve diseases in a smaller Hispanic
amily characterized by bicuspid aortic valve and aortic valve
alcification (Figs. 2D and 2E). The mutation, labeled
Genes
Chromosome
Band
Genetic
Variants
Effect
(Risk Allele)
d 100
age, gender,
ols
VDR 12q13.11 BsmI  (B)
 62 matched
er, BMI,
on, lipids)
APOA1 11q23–q24 A/G 
APOB 2p24-p23 Ins/del 
XbaI  (X)
APOE 19q13.2 isoforms  (E2)
41 matched
ender)
ESR1 6q25.1 918 T/C (PvuII)  (p)
351 G/A (XbaI) 
TGFB1 19q13.1 509 C/T (AocI) 
ith and 759 APOE 19q13.2 isoforms  (E4)
IL-10 1q31–q32 1082 G/A  (G)
819 C/T  (C)
592 C/A  (C)
CCR5 3p21.31 32 bp deletion 
CTGF 6q23.1 447 G/C 
index; CAD  coronary artery disease; ESR1  estrogen receptor ; IL  interleukin; TGFB1 n
ses an
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Genomics of AVS April 8, 2008:1327–36he protein before ending its formation prematurely (Fig.
F). Recently, 2 novel likely pathogenic NOTCH1 muta-
ions (p.T596M and p.P1797H) were reported in 2 sporadic
ases of bicuspid aortic valve (68). The Notch pathway is
nown to be involved in embryonic patterning, and from
hese genetic studies it has been documented to be highly
xpressed within the developing aortic valve. Moreover,
otch1 has been identified as a repressor of Runx2, a critical
egulator of osteoblast development. Thus, the discovery of
he Notch pathway in aortic valve disease supports the
oncept that a developmental program might be reactivated
n disease processes. Taken together, these results provide
ompelling evidence that functional deoxyribonucleic acid
ariants at the NOTCH1 locus result in human valve
iseases. However, a very limited number of patients as well
s deoxyribonucleic acid variants in the NOTCH1 gene
ave been studied. Whether genetic variants in that gene
ontribute to AVS in the population at large still remains to
e determined. Nevertheless, this work demonstrates the
tility of genetic research to identify new molecular targets.
lobal perspective of genetic research on AVS. Collec-
ively, molecular and genetic studies have clearly demon-
trated that AVS is not merely the result of a passive process
ssociated with aging but rather an active pathobiological
isorder with several potential therapeutic targets. As pre-
Figure 2 NOTCH1 Mutations Segregate With Familial Aortic Va
(A) Kindred with 5 generations (indicated with Roman numerals) affected by conge
are indicated numerically. Deceased family members (slash) were unavailable for
family members. AI  aortic insufficiency; AV  aortic valve; AVS  aortic stenosi
defect. (C) Sequence chromatogram of affected family members. (D) Kindred with
DORV  double-outlet right ventricle; HLV  hypoplastic left ventricle; MA  mitra
family B. (G) Schematic drawings of normal trileaflet aortic valve, bicuspid aortic v
Garg V, Muth AN, Ransom JF, et al. Mutations in NOTCH1 cause aortic valve diseaiously emphasized, many factors are involved in the devel- apment of AVS. At the moment, convincing evidence
upports the hypothesis that, in at least a subset of individ-
als, genetic predisposition co-exists along with environ-
ental factors to create a biological substrate prone to early
alcification of the aortic valve. In fact, genetic association
tudies performed with candidate genes and the identifica-
ion of signaling pathways such as Runx2/Cbfa1, Wnt, nitric
xide, and Notch1 provide some landmarks for understand-
ng the pathogenesis of AVS (Fig 1). However, further
esearch will be required to understand the molecular basis
f the disease.
Except for NOTCH1, all of the genes investigated so far
ere identified by a candidate gene strategy. In this ap-
roach, genes are selected according to their known func-
ions. As a result of current concepts of AVS pathogenesis,
eneticists have studied genes involved in calcification
VDR and CTGF), inflammation (IL-10 and CCR-5), and
issue remodeling (TGF-1) as well as genes influencing
ipids and lipoprotein metabolism (APOE, APOB, and
SR1). It is still too early to know whether a final common
athway will be identified from genetic research or whether
t is a true polygenic disease. To elucidate this question,
any more genes encoding components of pathological
athways leading to AVS remain to be tested. These include
enes involved in subendothelial deposition and retention of
isease
eart disease and valve calcification. Participating members of each generation
on analysis. Square  male; circle  female. (B) Cardiac phenotype in affected
 bicuspid aortic valve; TOF  tetralogy of Fallot; VSD  ventricular septal
mbers affected by congenital heart disease. (E) Cardiac phenotype of family B.
ia; MS  mitral stenosis. (F) Sequence chromatogram of affected members in
nd calcified aortic valve. Reprinted with permission from Macmillan Publishers:
ature 2005;437:270–4.lve D
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3 me
l atres
alve, a
se. Ntherogenic lipoproteins, chronic inflammation, the renin-
a
i
n
g
i
f
t
g
q
t
e
y
A
R
I
b
e
s
c
d
t
H
o
e
g
s
i
p
i
b
h
A
o
R
g
c
u
s
a
m
e
c
a
e
c
d
t
t
c
f
s
p
(
o
f
o
p
h
c
t
d
i
b
c
B
f
a
t
v
e
p
f
p
A
g
p
m
G
s
t
i
i
M
c
m
F
g
p
t
t
d
h
p
d
d
t
a
s
c
t
3
o
c
f
a
a
i
c
1333JACC Vol. 51, No. 14, 2008 Bossé et al.
April 8, 2008:1327–36 Genomics of AVSngiotensin system, remodeling, fibrosis, and neovascular-
zation as well as specific cell signaling pathways regulating
itric oxide and ectopic calcification. In addition, different
enes may act at different stages of the disease. For example,
t is expected that the genes involved in early lesion
ormation will be found to differ from those involved later in
he calcification process. Obviously, a substantial amount of
enetic research will be required to answer these critical
uestions. Recent developments in genomic research and
echnologies are particularly promising and may well accel-
rate the pace of discovery. Unfortunately, these tools have
et to be applied to AVS.
dvances in Genomic
esearch and Applications in AVS
ndividualized medicine has been marked as one of the
enefits of the Human Genome Project (69) and the
nsuing International HapMap Project (66). Early genetic
tudies were impaired by our inability to comprehensively
apture genetic variability. The bottleneck was our misun-
erstanding of human genetic variations and our incapacity
o measure them. With the premise of the International
apMap project and the recent boost in technology devel-
pments, these limitations have been overcome to some
xtent. It is now possible to interrogate the entire human
enome and capture most of the genetic information in 1
imple assay. The power of these new genomic approaches
s in the ability to interrogate the genetic component of a
articular disease without prior knowledge of the biolog-
cal basis governing it. In the subsequent sections, we
riefly describe these new tools. In particular, we show
ow they can be applied to improve our understanding of
VS, including the diagnosis, prevention, and treatment
f patients.
NA profiling with microarrays. Recent developments in
enomic technologies have motivated many researchers to
ompile gene expression profiles in different tissue samples
sing microarray technology. This powerful technology
erves 2 main purposes in the disease state: 1) gene discovery
nd; 2) molecular signature analysis. Substantial improve-
ent and standardization have been achieved in gene
xpression research in the last few years. The arrays that are
urrently available can scan the expression levels of almost
ll genes in the human genome simultaneously, and they
xhibit good intraplatform consistency and a high level of
oncordance in term of the genes identified as being
ifferentially expressed (70). In addition, new bioinformatics
ools are now available to visualize gene expression data in
he context of biological pathways (71,72). Previous mi-
roarray studies showed that gene expression profiles dif-
ered considerably among patients at various temporal and
patial points of the disease. For example, heart failure
rofiles varied among patients of different age and gender
73). Similarly, different gene expression signatures were
bserved in transgenic mice at different stages of heart gailure (74). Future application of this technology on a range
f healthy to severely affected aortic valve tissues is likely to
roduce a comprehensive list of dysregulated genes and
ighlight the transcriptional profile leading to the disease.
Recent studies suggested that blood-cell–derived ribonu-
leic acid can be used as an alternative to direct sampling of
issue biopsies to find molecular signatures of internal
iseases (75–79). It is likely that the calcification and the
nflammatory processes involved in AVS are reflected in
lood cells. The gene expression profiles of circulating cells
an potentially provide an early warning of eventual threats.
lood-cell–derived ribonucleic acid offers many advantages
or research and clinical applications. First, human blood is
noninvasive readily available source of clinical materials
hat can be collected in sufficient quantity. In contrast to
alve tissues that are obtained from patients only after
xplantation, human blood can be collected at various time
oints and consequently has more direct clinical applications
or disease management. In addition, the investigation of
eripheral blood allows for gene profiling of larger samples.
ccordingly, exploring deoxyribonucleic acid microarray
ene expression in whole blood may potentially become a
owerful tool for researching, diagnosing and treating hu-
an AVS.
enotyping technologies and genome-wide association
tudies. The technology boost in genomic research can be
ruly appreciated in genotyping applications (80). Genotyp-
ng refers to the process of determining the genotype of an
ndividual and is used to identify disease-associated genes.
any methodologies have been developed, using different
hemistries and instrumentations. The majority of these
ethods genotype only a tiny fraction of the human genome.
or example, genetic association studies conducted on AVS
enotyped 1 to 3 single nucleotide polymorphism (SNPs)
er gene (Table 1). This is a very limiting approach, given
hat millions of such variants exist in the human genome. At
he time of writing (October 2007), the public SNP
atabase known as dbSNP contained 11.9 million candidate
uman SNPs. According to the International HapMap
roject (66), a large fraction of these SNPs provide redun-
ant information, which gives rise to the concept of linkage
isequilibrium. The high level of linkage disequilibrium in
he human genome is encouraging as far as genome-wide
ssociation studies are concerned. A maximally informative
et of SNPs, or a scientifically selected subset of all SNPs,
an be genotyped to capture nearly all common variations in
he human genome. Previous estimates suggested that
00,000 to 500,000 SNPs are required to achieve this level
f coverage (66). Although these numbers seem impressive,
urrent technologies can afford a lot more. Different plat-
orms now allow millions of SNPs to be assessed in a single
ssay. With this high-density coverage, these platforms can
lso identify copy number variations that are likely to be
nvolved in complex diseases (81,82). Thus, unprecedented
apabilities are currently available to interrogate the human
enome. The power of such hypothesis-free study designs in
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Genomics of AVS April 8, 2008:1327–36dentifying the genetic factors of complex diseases is only
ust beginning to emerge for certain diseases, such as obesity
83), type 2 diabetes (84), and Crohn disease (85). However,
ntensive effort will be required, and resources will have to
e consolidated, for a genome-wide association study on
VS.
Although promising, the cost of failure with genome-
ide association scans is potentially huge for studies that are
esigned and executed with low statistical power and
nadequate quality control (86). In addition, the approach is
urrently biased to detect common susceptibility variants
ather than the entire allelic spectrum of human diseases
87). For example, susceptibility alleles with minor allele
requencies of 5% or with effect sizes of 1.2 odds ratio
re not likely to be found unless they are tested in unreal-
stically large sample sizes. However, the major limitation of
enome-wide association studies is the cost of phenotyping
nd genotyping thousands of individuals. The establishment
f an international consortium is timely to share the enormous
esearch resources required to conduct a well powered genome-
ide association screen on AVS. Consortia studies conducted
ith methodologic rigor are a practical approach to achieve
ufficiently large sample size (88). With the anticipation of
uch an endeavor in AVS, potential participating centers
ust adopt a clear classification for case and control subjects
hat is based on standards and widely accepted criteria.
enome-wide association scan studies on AVS would
ertainly accelerate susceptibility locus discovery and are
orth pursuing even if they are not expected to fully resolve
he allelic architecture that underlies this multifactorial
uman disease.
onclusions
 clear genetic component of AVS is anticipated. So far,
nly a handful of studies have attempted to unravel the
enetic architecture of AVS. A small number of candidate
enes, such as VDR, APOE, APOB, IL10, and ESR1, have
een identified but need to be confirmed in larger samples.
enetic research has also identified defects in the Notch1
ignaling pathway causing aortic valve diseases in a re-
tricted number of families. Basically, all genetic/genomic
ork on AVS is still at the embryonic stage. A major factor
imiting the progression of the field is the lack of large and
ell-defined case-control series of patients with AVS.
esources must be allocated to build these cohorts, because
he bottleneck in genomic research has shifted from an
ncapacity to measure genetic variations to an inability to
valuate them in appropriate cohorts. In fact, with techno-
ogic progress in genomic research, we are now able to
omprehensively interrogate the human genome and review
he pathogenesis of AVS using powerful tools. These tools
an confirm suspected targets and identify unsuspected
argets. These new targets improve our understanding of the
isease etiology and can be translated into many patient
enefits. In fact, drug targets can lead to the development ofew drugs that, in the longer term, have the potential to
roduce new therapeutic options. For patients, identifica-
ion of causal genes means that new clinical counselling
uidelines, including prevention strategies and better diag-
osis in families at greater risk, can be built.
Echocardiographic and clinical variables are not sufficient
o accurately predict the hemodynamic progression rate of
he stenosis. Therefore, the important interindividual
ariation in AVS progression rate remains largely unex-
lained. In this context, genomic research also has the
otential to discover genetic variants or biomarkers that
ould help the clinician to identify AVS patients who are
ikely to have rapid hemodynamic progression versus slow
r no progression.
Further insights into the genetic factors associated with
VS may also allow us to custom-tailor future medical
reatments. Ultimately, finding the causal genes will repre-
ent a major step forward in disease prevention and treat-
ent. However, to achieve its promise, genomic research
ill require large well designed studies that incorporate
igh-throughput genomic data and carefully collected
henotypes.
eprint requests and correspondence: Dr. Yohan Bossé, Laval
ospital Research Centre, Pavillon Margeritte-d’Youville, Y4190,
725, Chemin Sainte-Foy, Québec City, Québec, Canada G1V
G5. E-mail: yohan.bosse@crhl.ulaval.ca.
EFERENCES
1. Rosamond W, Flegal K, Friday G, et al. Heart disease and stroke
statistics—2007 update: a report from the American Heart Association
Statistics Committee and Stroke Statistics Subcommittee. Circulation
2007;115:e69–171.
2. Schoen FJ, Levy RJ. Calcification of tissue heart valve substitutes:
progress toward understanding and prevention. Ann Thorac Surg
2005;79:1072–80.
3. Supino PG, Borer JS, Preibisz J, Bornstein A. The epidemiology of
valvular heart disease: a growing public health problem. Heart Fail
Clin 2006;2:379–93.
4. Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG,
Enriquez-Sarano M. Burden of valvular heart diseases: a population-
based study. Lancet 2006;368:1005–11.
5. Roberts WC. Anatomically isolated aortic valvular disease. The case
against its being of rheumatic etiology. Am J Med 1970;49:151–9.
6. Passik CS, Ackermann DM, Pluth JR, Edwards WD. Temporal
changes in the causes of aortic stenosis: a surgical pathologic study of
646 cases. Mayo Clin Proc 1987;62:119–23.
7. Freeman RV, Otto CM. Spectrum of calcific aortic valve disease:
pathogenesis, disease progression, and treatment strategies. Circula-
tion 2005;111:3316–26.
8. Stewart BF, Siscovick D, Lind BK, et al. Clinical factors associated
with calcific aortic valve disease. Cardiovascular Health Study. J Am
Coll Cardiol 1997;29:630–4.
9. Otto CM, Lind BK, Kitzman DW, Gersh BJ, Siscovick DS. Associ-
ation of aortic-valve sclerosis with cardiovascular mortality and mor-
bidity in the elderly. N Engl J Med 1999;341:142–7.
0. Novaro GM, Katz R, Aviles RJ, et al. Clinical factors, but not
C-reactive protein, predict progression of calcific aortic-valve disease:
the Cardiovascular Health Study. J Am Coll Cardiol 2007;50:1992–8.
1. Lindroos M, Kupari M, Heikkila J, Tilvis R. Prevalence of aortic valve
abnormalities in the elderly: an echocardiographic study of a random
population sample. J Am Coll Cardiol 1993;21:1220–5.
11
1
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2
3
3
3
3
3
3
3
3
3
3
4
4
4
4
4
4
4
4
4
4
5
5
5
5
5
5
5
5
1335JACC Vol. 51, No. 14, 2008 Bossé et al.
April 8, 2008:1327–36 Genomics of AVS2. Otto CM, Burwash IG, Legget ME, et al. Prospective study of
asymptomatic valvular aortic stenosis. Clinical, echocardiographic, and
exercise predictors of outcome. Circulation 1997;95:2262–70.
3. Roberts WC, Ko JM. Frequency by decades of unicuspid, bicuspid,
and tricuspid aortic valves in adults having isolated aortic valve
replacement for aortic stenosis, with or without associated aortic
regurgitation. Circulation 2005;111:920–5.
4. Cowell SJ, Newby DE, Boon NA, Elder AT. Calcific aortic stenosis:
same old story? Age Ageing 2004;33:538–44.
5. Beppu S, Suzuki S, Matsuda H, Ohmori F, Nagata S, Miyatake K.
Rapidity of progression of aortic stenosis in patients with congenital
bicuspid aortic valves. Am J Cardiol 1993;71:322–7.
6. Aronow WS, Ahn C, Kronzon I, Goldman ME. Association of
coronary risk factors and use of statins with progression of mild
valvular aortic stenosis in older persons. Am J Cardiol 2001;88:693–5.
7. Palta S, Pai AM, Gill KS, Pai RG. New insights into the progression
of aortic stenosis: implications for secondary prevention. Circulation
2000;101:2497–502.
8. Katz R, Wong ND, Kronmal R, et al. Features of the metabolic
syndrome and diabetes mellitus as predictors of aortic valve calcifica-
tion in the Multi-ethnic Study of Atherosclerosis. Circulation 2006;
113:2113–9.
9. Briand M, Lemieux I, Dumesnil JG, et al. Metabolic syndrome
negatively influences disease progression and prognosis in aortic
stenosis. J Am Coll Cardiol 2006;47:2229–36.
0. Sell S, Scully RE. Aging changes in the aortic and mitral valves:
histologic and histochemical studies, with observations on the patho-
genesis of calcific aortic stenosis and calcification of the mitral annulus.
Am J Pathol 1965;46:345–65.
1. Mathieu P, Voisine P, Pepin A, Shetty R, Savard N, Dagenais F.
Calcification of human valve interstitial cells is dependent on alkaline
phosphatase activity. J Heart Valve Dis 2005;14:353–7.
2. Rajamannan NM, Gersh B, Bonow RO. Calcific aortic stenosis: from
bench to the bedside—emerging clinical and cellular concepts. Heart
2003;89:801–5.
3. O’Brien KD. Pathogenesis of calcific aortic valve disease: a disease
process comes of age (and a good deal more). Arterioscler Thromb
Vasc Biol 2006;26:1721–8.
4. Shetty R, Pepin A, Charest A, et al. Expression of bone-regulatory
proteins in human valve allografts. Heart 2006;92:1303–8.
5. Caira FC, Stock SR, Gleason TG, et al. Human degenerative valve
disease is associated with up-regulation of low-density lipoprotein
receptor-related protein 5 receptor-mediated bone formation. J Am
Coll Cardiol 2006;47:1707–12.
6. O’Brien KD, Shavelle DM, Caulfield MT, et al. Association of
angiotensin-converting enzyme with low-density lipoprotein in aortic
valvular lesions and in human plasma. Circulation 2002;106:2224–30.
7. Rajamannan NM, Subramaniam M, Rickard D, et al. Human aortic
valve calcification is associated with an osteoblast phenotype. Circu-
lation 2003;107:2181–4.
8. O’Brien KD, Reichenbach DD, Marcovina SM, Kuusisto J, Alpers
CE, Otto CM. Apolipoproteins B, (a), and E accumulate in the
morphologically early lesion of “degenerative” valvular aortic stenosis.
Arterioscler Thromb Vasc Biol 1996;16:523–32.
9. Helske S, Lindstedt KA, Laine M, et al. Induction of local angiotensin
II-producing systems in stenotic aortic valves. J Am Coll Cardiol
2004;44:1859–66.
0. Olsson M, Thyberg J, Nilsson J. Presence of oxidized low density
lipoprotein in nonrheumatic stenotic aortic valves. Arterioscler
Thromb Vasc Biol 1999;19:1218–22.
1. Kaden JJ, Dempfle CE, Grobholz R, et al. Interleukin-1 beta
promotes matrix metalloproteinase expression and cell proliferation in
calcific aortic valve stenosis. Atherosclerosis 2003;170:205–11.
2. Kaden JJ, Dempfle CE, Grobholz R, et al. Inflammatory regulation of
extracellular matrix remodeling in calcific aortic valve stenosis. Car-
diovasc Pathol 2005;14:80–7.
3. Edep ME, Shirani J, Wolf P, Brown DL. Matrix metalloproteinase
expression in nonrheumatic aortic stenosis. Cardiovasc Pathol 2000;9:
281–6.
4. Charest A, Pepin A, Shetty R, et al. Distribution of SPARC during
neovascularisation of degenerative aortic stenosis. Heart 2006;92:
1844–9.5. Hinton RB Jr., Lincoln J, Deutsch GH, et al. Extracellular matrix
remodeling and organization in developing and diseased aortic valves.
Circ Res 2006;98:1431–8.
6. Mohler ER 3rd. Are atherosclerotic processes involved in aortic-valve
calcification? Lancet 2000;356:524–5.
7. Pinzar E, Wang T, Garrido MR, Xu W, Levy P, Bottari SP.
Angiotensin II induces tyrosine nitration and activation of ERK1/2 in
vascular smooth muscle cells. FEBS Lett 2005;579:5100–4.
8. Weiss RM, Ohashi M, Miller JD, Young SG, Heistad DD. Calcific
aortic valve stenosis in old hypercholesterolemic mice. Circulation
2006;114:2065–9.
9. Rajamannan NM, Subramaniam M, Stock SR, et al. Atorvastatin
inhibits calcification and enhances nitric oxide synthase production in
the hypercholesterolaemic aortic valve. Heart 2005;91:806–10.
0. Lee TC, Zhao YD, Courtman DW, Stewart DJ. Abnormal aortic
valve development in mice lacking endothelial nitric oxide synthase.
Circulation 2000;101:2345–8.
1. Steiner I, Kasparova P, Kohout A, Dominik J. Bone formation in
cardiac valves: a histopathological study of 128 cases. Virchows Arch
2007;450:653–7.
2. Bone formation and inflammation in cardiac valves. Circulation
2001;103:1522–8.
3. O’Brien KD, Kuusisto J, Reichenbach DD, et al. Osteopontin is
expressed in human aortic valvular lesions. Circulation 1995;92:
2163–8.
4. Rajamannan NM, Subramaniam M, Springett M, et al. Atorvastatin
inhibits hypercholesterolemia-induced cellular proliferation and bone
matrix production in the rabbit aortic valve. Circulation 2002;105:
2660–5.
5. Steitz SA, Speer MY, Curinga G, et al. Smooth muscle cell pheno-
typic transition associated with calcification: upregulation of Cbfa1
and downregulation of smooth muscle lineage markers. Circ Res
2001;89:1147–54.
6. Ducy P, Zhang R, Geoffroy V, Ridall AL, Karsenty G. Osf2/Cbfa1:
a transcriptional activator of osteoblast differentiation. Cell 1997;89:
747–54.
7. Kaden JJ, Bickelhaupt S, Grobholz R, et al. Expression of bone
sialoprotein and bone morphogenetic protein-2 in calcific aortic
stenosis. J Heart Valve Dis 2004;13:560–6.
8. Rajamannan NM, Subramaniam M, Caira F, Stock SR, Spelsberg
TC. Atorvastatin inhibits hypercholesterolemia-induced calcification
in the aortic valves via the Lrp5 receptor pathway. Circulation
2005;112:I229–34.
9. Clementi M, Notari L, Borghi A, Tenconi R. Familial congenital
bicuspid aortic valve: a disorder of uncertain inheritance. Am J Med
Genet 1996;62:336–8.
0. Huntington K, Hunter AG, Chan KL. A prospective study to assess
the frequency of familial clustering of congenital bicuspid aortic valve.
J Am Coll Cardiol 1997;30:1809–12.
1. Cripe L, Andelfinger G, Martin LJ, Shooner K, Benson DW.
Bicuspid aortic valve is heritable. J Am Coll Cardiol 2004;44:138–43.
2. Martin LJ, Ramachandran V, Cripe LH, et al. Evidence in favor of
linkage to human chromosomal regions 18q, 5q and 13q for bicuspid
aortic valve and associated cardiovascular malformations. Hum Genet
2007;121:275–84.
3. Wessels MW, Berger RM, Frohn-Mulder IM, et al. Autosomal
dominant inheritance of left ventricular outflow tract obstruction.
Am J Med Genet A 2005;134:171–9.
4. McBride KL, Pignatelli R, Lewin M, et al. Inheritance analysis of
congenital left ventricular outflow tract obstruction malformations:
segregation, multiplex relative risk, and heritability. Am J Med Genet
A 2005;134:180–6.
5. Horne BD, Camp NJ, Muhlestein JB, CannonAlbright LA. Evidence
for a heritable component in death resulting from aortic and mitral
valve diseases. Circulation 2004;110:3143–8.
6. Le Gal G, Bertault V, Bezon E, Cornily JC, Barra JA, Blanc JJ.
Heterogeneous geographic distribution of patients with aortic valve
stenosis: arguments for new aetiological hypothesis. Heart 2005;91:
247–9.
7. Probst V, Le Scouarnec S, Legendre A, et al. Familial aggregation of
calcific aortic valve stenosis in the western part of France. Circulation
2006;113:856–60.
55
6
6
6
6
6
6
6
6
6
6
7
7
7
7
7
7
7
7
7
7
8
8
8
8
8
8
8
8
8
1336 Bossé et al. JACC Vol. 51, No. 14, 2008
Genomics of AVS April 8, 2008:1327–368. Ortlepp JR, Hoffmann R, Ohme F, Lauscher J, Bleckmann F,
Hanrath P. The vitamin D receptor genotype predisposes to the
development of calcific aortic valve stenosis. Heart 2001;85:635–8.
9. Novaro GM, Sachar R, Pearce GL, Sprecher DL, Griffin BP.
Association between apolipoprotein E alleles and calcific valvular heart
disease. Circulation 2003;108:1804–8.
0. Nordström P, Glader CA, Dahlen G, et al. Oestrogen receptor alpha
gene polymorphism is related to aortic valve sclerosis in postmeno-
pausal women. J Intern Med 2003;254:140–6.
1. Avakian SD, Annicchino-Bizzacchi JM, Grinberg M, Ramires JA,
Mansura AP. Apolipoproteins AI, B, and E polymorphisms in severe
aortic valve stenosis. Clin Genet 2001;60:381–4.
2. Ortlepp JR, Schmitz F, Mevissen V, et al. The amount of calcium-
deficient hexagonal hydroxyapatite in aortic valves is influenced by
gender and associated with genetic polymorphisms in patients with
severe calcific aortic stenosis. Eur Heart J 2004;25:514–22.
3. Freely associating. Nat Genet 1999;22:1–2.
4. Hegele RA. SNP judgments and freedom of association. Arterioscler
Thromb Vasc Biol 2002;22:1058–61.
5. Wacholder S, Chanock S, Garcia-Closas M, El Ghormli L, Rothman
N. Assessing the probability that a positive report is false: an approach
for molecular epidemiology studies. J Natl Cancer Inst 2004;96:434–
42.
6. A haplotype map of the human genome. Nature 2005;437:1299–320.
7. Garg V, Muth AN, Ransom JF, et al. Mutations in NOTCH1 cause
aortic valve disease. Nature 2005;437:270–4.
8. Mohamed SA, Aherrahrou Z, Liptau H, et al. Novel missense
mutations (p.T596M and p.P1797H) in NOTCH1 in patients with
bicuspid aortic valve. Biochem Biophys Res Commun 2006;345:
1460–5.
9. Finishing the euchromatic sequence of the human genome. Nature
2004;431:931–45.
0. Shi L, Reid LH, Jones WD, et al. The MicroArray Quality Control
(MAQC) project shows inter- and intraplatform reproducibility of
gene expression measurements. Nat Biotechnol 2006;24:1151–61.
1. Calvano SE, Xiao W, Richards DR, et al. A network-based analysis of
systemic inflammation in humans. Nature 2005;437:1032–7.
2. Dahlquist KD, Salomonis N, Vranizan K, Lawlor SC, Conklin BR.
GenMAPP, a new tool for viewing and analyzing microarray data on
biological pathways. Nat Genet 2002;31:19–20.
3. Boheler KR, Volkova M, Morrell C, et al. Sex- and age-dependent
human transcriptome variability: implications for chronic heart failure.
Proc Natl Acad Sci U S A 2003;100:2754–9.4. Tang Z, McGowan BS, Huber SA, et al. Gene expression profiling
during the transition to failure in TNF-alpha over-expressing mice
demonstrates the development of autoimmune myocarditis. J Mol Cell
Cardiol 2004;36:515–30.
5. Gladkevich A, Nelemans SA, Kauffman HF, Korf J. Microarray
profiling of lymphocytes in internal diseases with an altered immune
response: potential and methodology. Mediators Inflamm 2005;2005:
317–30.
6. Whitney AR, Diehn M, Popper SJ, et al. Individuality and variation in
gene expression patterns in human blood. Proc Natl Acad Sci U S A
2003;100:1896–901.
7. Twine NC, Stover JA, Marshall B, et al. Disease-associated expression
profiles in peripheral blood mononuclear cells from patients with
advanced renal cell carcinoma. Cancer Res 2003;63:6069–75.
8. DePrimo SE, Wong LM, Khatry DB, et al. Expression profiling of
blood samples from an SU5416 phase III metastatic colorectal cancer
clinical trial: a novel strategy for biomarker identification. BMC
Cancer 2003;3:3.
9. Horwitz PA, Tsai EJ, Putt ME, et al. Detection of cardiac allograft
rejection and response to immunosuppressive therapy with peripheral
blood gene expression. Circulation 2004;110:3815–21.
0. Syvanen AC. Toward genome-wide SNP genotyping. Nat Genet
2005;37 Suppl:S5–10.
1. Redon R, Ishikawa S, Fitch KR, et al. Global variation in copy number
in the human genome. Nature 2006;444:444–54.
2. Wong KK, deLeeuw RJ, Dosanjh NS, et al. A comprehensive analysis
of common copy-number variations in the human genome. Am J Hum
Genet 2007;80:91–104.
3. Herbert A, Gerry NP, McQueen MB, et al. A common genetic variant
is associated with adult and childhood obesity. Science 2006;312:279–
83.
4. Sladek R, Rocheleau G, Rung J, et al. A genome-wide association
study identifies novel risk loci for type 2 diabetes. Nature 2007;445:
881–5.
5. Rioux JD, Xavier RJ, Taylor KD, et al. Genome-wide association
study identifies new susceptibility loci for Crohn disease and implicates
autophagy in disease pathogenesis. Nat Genet 2007;39:596–604.
6. Hirschhorn JN, Daly MJ. Genome-wide association studies for com-
mon diseases and complex traits. Nat Rev Genet 2005;6:95–108.
7. Wang WY, Barratt BJ, Clayton DG, Todd JA. Genome-wide
association studies: theoretical and practical concerns. Nat Rev Genet
2005;6:109–18.
8. Chanock SJ, Manolio T, Boehnke M, et al. Replicating genotype-
phenotype associations. Nature 2007;447:655–60.
